Shanghai Public Health Clinical Center
73
7
8
22
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
1.4%
1 terminated/withdrawn out of 73 trials
95.7%
+9.1% vs industry average
36%
26 trials in Phase 3/4
9%
2 of 22 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (73)
Prevention of AIDS With Opportunistic Infection Paradoxical IRIS
Role: lead
A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
Role: collaborator
Real-world Cohort Study of Antiretroviral Therapy in HIV Patients With Opportunistic Infections
Role: lead
Incidence of Liver Disease-Related Outcomes in People With HIV
Role: lead
Shanghai Clinical Cohort - Adrenal Disease
Role: collaborator
Multicenter Clinical Translational Study of "ICU-NO CRBSI" Based on Improvement Science
Role: collaborator
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Role: collaborator
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
Role: lead
Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis
Role: lead
Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers
Role: collaborator
Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant
Role: lead
A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB
Role: collaborator
Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma
Role: collaborator
The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis
Role: collaborator
A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML
Role: collaborator
Allogeneic Adoptive Immune Therapy for Advanced AIDS Patients
Role: collaborator
Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection
Role: lead
Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)
Role: collaborator
Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder
Role: lead
Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression
Role: lead